[ad_1]
MADRID, 27 (EUROPA PRESS)
AbbVie and the Medicines Patent Group (MPP) Sign New Fee-Free Licensing Agreement to Accelerate Access to Hepatitis C Pangenetic Treatment for Hepatitis C, Glecaprevir / Pibrentasvir (G / P) 99 Income Countries medium and low.
With this agreement, AbbVie will grant generic drug companies deemed appropriate by the World Health Organization (WHO) license, manufacture and supply of generic versions of the treatment, while maintaining high production and manufacturing standards. quality of the company.
"The availability of a pangenotypic and 8-week treatment guideline for the majority of patients with the hepatitis C virus is essential to advance prioritization, access and control efforts." 39, elimination of HCV in the world and thus achieve the goals set by WHO to eliminate hepatitis C by 2030, "said AbbVie Care and Community Relations Director of AbbVie Spain, Belén López.
This collaboration of biopharmaceutical company AbbVie is part of its global commitment to ensuring long-term access to different treatments for infectious diseases around the world. In this sense, Lopez has ensured that this type of agreements promotes "sustainable" solutions to achieve the elimination of the virus around the world.
"AbbVie, in its commitment to eliminating hepatitis C, works hand in hand with governments, patient organizations, public health experts and other interested parties to help address unmet needs in this area. ", did he declare.
[ad_2]
Source link
